ret Oncoprotein Novocastra
The ret proto-oncogene encodes a cell surface glycoprotein belonging to the receptor tyrosine kinase family and is located on chromosome 10q11.2. Three main 3' splice isoforms have been characterized from papillary thyroid carcinomas, themselves originating from thyroid epithelial cells. Ret expression is reported in several regions of the central nervous system; in the developing cranial nerve ganglia and a subset of cells within dorsal root ganglia, in motor neurons in the spinal cord and hindbrain, in neuroretina and the growing tips of the renal collecting ducts in developing kidney. Some individuals with Hirschsprung's disease have severe developmental abnormalities of the kidney and these phenotypic abnormalities may be linked with mutations of ret proto-oncogene. About 70 percent of individuals who carry one of the documented ret mutations that predispose to multiple endocrine neoplasia type II (MENII) will develop thyroid C cell derived tumors in their lifetime.
Product Specific Information
NCL-RET was raised to the intracellular domain of the molecule, present in all isoforms of the protein. Mutations are reported to occur upstream of this domain.
|RET-U||1ml NCL-RET US IVD||Lyophilised Concentrated Monoclonal Antibody||P(HIER)||Info||MSDS||1|
|RET||1ml NCL-RET||Lyophilised Concentrated Monoclonal Antibody||P(HIER)||Info||MSDS||1|
|RET-S||0.1ml NCL-RET||Lyophilised Concentrated Monoclonal Antibody||P(HIER)||Info||MSDS||1|